التفاصيل البيبلوغرافية
| العنوان: |
ERΒ IS A POSSIBLE BIOMARKER OF BREAST CANCER. |
| المؤلفون: |
Ana, Božović, Milica, Nedeljković, Bojana, Kožik, Lidija, Todorović, Milena, Krajnović, Snežana, Jovanović-Ćupić, Nikola, Kokanov, Vesna, Mandušić |
| المصدر: |
Genetics & Applications; 2024 Special Issue, p28-28, 1p |
| مصطلحات موضوعية: |
BREAST cancer, EPIDERMAL growth factor receptors, BIOMARKERS, MEDIAN (Mathematics), PROGESTERONE receptors |
| مصطلحات جغرافية: |
SERBIA |
| مستخلص: |
Breast cancer (BC) is the most common cancer among women worldwide. The diagnosis and treatment decisions depend on the three biomarkers: oestrogen receptor alfa, progesterone receptor and human epidermal growth factor 2. The foremost treatment line is Nolvadex (tamoxifen). Yet approximately 30% of patients do not respond to tamoxifen treatment. The discovery of oestrogen receptor beta (ERβ) opened the door for another BC biomarker’s introduction. The studies show that the ERβ usually behaves like a tumour suppressor and that its expression is a favourable parameter of the patient survival and treatment response. Our study aimed to assess the prognostic and predictive role of ERβ in BC. It encompassed 118 BC samples from patients operated at the Institute of Oncology and Radiology of Serbia from 2002 to 2004. Overall (OS) and disease-free survival (DFS) data were collected between 2002 and 2022. We used the Western blot method for ERβ1 protein detection. The ERβ1 mRNA and ERβ delta5 mRNA isoforms were detected by quantitative PCR method with TaqMan Assays. The extracted DNA was subjected to a two-step MSP MethEvaGreen procedure, using primers we designed to detect specific ERβ gene promoter ON methylation. Patient groups were divided into low and high-expression groups based on median values. Our results showed that in the high methylation index group, OS and DFS of patients who received adjuvant Nolvadex treatment were significantly longer than those who did not (p=0.001, p=0.033, respectively). In the low methylation index group, the DFS of patients who received radiotherapy was significantly shorter than those who did not (p=0.037). However, in the low ERβ mRNA expression group, the DFS of patients who received radiotherapy was significantly shorter than those who did not (p=0.028). Our results show that ERβ could be a significant additional parameter in the BC prognosis and treatment decisions. Further analyses are needed. [ABSTRACT FROM AUTHOR] |
|
Copyright of Genetics & Applications is the property of Genetics & Applications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder